Editas Medicine, Inc. (EDIT)

NMS – Цена в реальном времени. Валюта: USD

2.93

-0.13 (-4.25%)

При закрытии: May 12, 2026, 4:00 PM EDT

2.94

+0.01 (0.34%)

До открытия: May 13, 2026, 9:11 AM EDT

Обзор
Новости
График
Финансы
Дивиденды
Прогноз
Владельцы
Профиль

Editas Medicine, Inc. (EDIT)

Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Finranks

Компания

Контакты

Мы в соцсетях

Editas Medicine, Inc. (EDIT)

EDIT's Q1 Loss Narrower Than Expected, Pipeline in Focus

Editas Medicine (EDIT) Reports Q1 Loss, Misses Revenue Estimates

Editas Medicine Announces First Quarter 2026 Results and Business Updates

Editas Medicine to Present New Preclinical Data Demonstrating Progress of EDIT-401 as Potential Treatment for Hyperlipidemia at Upcoming Scientific Conferences

Why Investors Need to Take Advantage of These 2 Medical Stocks Now

Editas (EDIT) Up 3.8% Since Last Earnings Report: Can It Continue?

Editas Medicine Announces U.S. Patent and Trademark Office Reaffirms its Prior Decision in Favor of the Broad Institute in CRISPR/Cas9 Interference

Видео

No Data

Пресс-релизы

Editas Medicine Announces First Quarter 2026 Results and Business Updates

Editas Medicine Announces U.S. Patent and Trademark Office Reaffirms its Prior Decision in Favor of the Broad Institute in CRISPR/Cas9 Interference

Editas Medicine Announces Fourth Quarter and Full Year 2025 Results and Business Updates

Genflow Biosciences PLC Announces Directorate Change

Search stocks

Editas Medicine, Inc. (EDIT)

Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Finranks

Компания

Контакты

Мы в соцсетях

Editas Medicine, Inc. (EDIT)

EDIT's Q1 Loss Narrower Than Expected, Pipeline in Focus

Editas Medicine (EDIT) Reports Q1 Loss, Misses Revenue Estimates

Editas Medicine Announces First Quarter 2026 Results and Business Updates

Editas Medicine to Present New Preclinical Data Demonstrating Progress of EDIT-401 as Potential Treatment for Hyperlipidemia at Upcoming Scientific Conferences

Why Investors Need to Take Advantage of These 2 Medical Stocks Now

Editas (EDIT) Up 3.8% Since Last Earnings Report: Can It Continue?

Editas Medicine Announces U.S. Patent and Trademark Office Reaffirms its Prior Decision in Favor of the Broad Institute in CRISPR/Cas9 Interference

Видео

No Data

Пресс-релизы

Editas Medicine Announces First Quarter 2026 Results and Business Updates

Editas Medicine Announces U.S. Patent and Trademark Office Reaffirms its Prior Decision in Favor of the Broad Institute in CRISPR/Cas9 Interference

Editas Medicine Announces Fourth Quarter and Full Year 2025 Results and Business Updates

Genflow Biosciences PLC Announces Directorate Change